JERUSALEM--(BUSINESS WIRE)--May 5, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA - News) announced today, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone® reached a record $329 million in the first quarter ended March 31, 2006. Once again, Copaxone® was the fastest growing multiple sclerosis (MS) therapy worldwide, with a growth of 29% in sales over the comparable quarter of 2005.
